Immunogenicity of an interferon-β1a product

International Journal of Immunopathology and Pharmacology

Volumn 24, Issue 2, 2011, Pages 499-504

  Kauffman, Marcelo A ^a   Sterin Prync, A ^b   Papouchado, M ^b   Gonzalez E ^c   Vidal, A J ^b   Grossberg, S E ^d   Chuppa, S ^d   Odoriz, B ^e   Vrech, C ^f   Diez, R A ^b   Ferro, H H ^b  

^a Sanatorio V Franchin ^*  (Argentina)

^b Bio Sidus   (Argentina)

^c Ciudad Autonoma de Buenos Aires   (Argentina)

^d MEDICAL COLLEGE OF WISCONSIN   (United States)

^e Hospital Central Mendoza   (Argentina)

^f Sanatorio Allende   (Argentina)

Author keywords

Binding antibodies; Immunogenicity; Interferon beta; Multiple sclerosis; Neutralizing antibodies

Indexed keywords

BETA1A INTERFERON; BLASTOFERON; EPITOPE; INTERFERON ANTIBODY; INTERFERON BETA SERINE; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; POLYCLONAL ANTIBODY; UNCLASSIFIED DRUG; BETA INTERFERON; IMMUNOLOGICAL ADJUVANT;

ANTIBODY BLOOD LEVEL; ANTIBODY PRODUCTION; ARTICLE; BIOASSAY; CANCER CELL; CONTROLLED STUDY; CYTOPATHOGENIC EFFECT; DRUG SURVEILLANCE PROGRAM; ENCEPHALOMYOCARDITIS VIRUS; ENZYME IMMUNOASSAY; HUMAN; HUMAN CELL; IMMUNOGENICITY; IN VIVO STUDY; MULTIPLE SCLEROSIS; NONHUMAN; PRIORITY JOURNAL; SERUM; VIRUS CULTURE; VIRUS INHIBITION; WORLD HEALTH ORGANIZATION; BLOOD; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITOPE MAPPING; IMMUNOLOGY; LETTER; PATHOGENICITY; SERODIAGNOSIS; TUMOR CELL LINE; ANTIBODY DETECTION; ANTIBODY TITER; ANTIGEN BINDING; CLINICAL ARTICLE; HUMAN CELL CULTURE;

ADJUVANTS, IMMUNOLOGIC; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; CELL LINE, TUMOR; CYTOPATHOGENIC EFFECT, VIRAL; ENCEPHALOMYOCARDITIS VIRUS; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPE MAPPING; EPITOPES; HUMANS; INTERFERON-BETA; MULTIPLE SCLEROSIS; NEUTRALIZATION TESTS;

EID: 80051780322     PISSN: 03946320     EISSN: None     Source Type: Journal    
DOI: 10.1177/039463201102400223     Document Type: Article

References (15)

1. Ponce R, Abad L, Amaravadi L, et al. Immunogenicity of biologically-derived therapeutics: assessment and interpretation of nonclinical safety studies. Regul Toxicol Pharmacol 2009; 54:164-82.
2. Hermeling S, Crommelin DJ, Schellekens H, Jiskoot W. Structure- immunogenicity relationships of therapeutic proteins. Pharm Res 2004; 21:897-03.
3. Prync AE, Yankilevich P, Barrero PR, et al. Two recombinant human interferon-beta la pharmaceutical preparations produce a similar transcriptional response determined using whole genome microarray analysis. Int J Clin Pharmacol Ther 2008; 46:64-71. (Pubitemid 351233791)
4. Schellekens H. Bioequivalence and the immunogenicity of biopharmaceuticals. Nat Rev Drug Discov 2002; 1:457-62. (Pubitemid 37361488)
5. Redlich PN, Grossberg SE. Analysis of antigenic domains on natural and recombinant human IFN-beta by the inhibition of biologic activities with monoclonal antibodies. J Immunol 1989; 143:1887-93. (Pubitemid 19241203)
6. Redlich PN, Grossberg SE. Immunochemical characterization of antigenic domains on human interferon-beta: spatially distinct epitopes are associated with both antiviral and antiproliferative activities. Eur J Immunol 1990; 20:1933-9. (Pubitemid 20355614)
7. Calam D, Drozdov S, Gust ID. World Health Organization Expert Committee on Biological Standardization. 45th report Antibodies to human interferon alfa and beta. World Health Organ Tech Rep 1995; 858:11.
8. Grossberg S, Taylor J, Siebenlist R, Jameson P. Biological & Immunological assays of human interferons In The Manual of Clinical Immunology. American Society of Microbiology Publishing, Washington DC 1986; p. 295-99.
9. Grossberg SE, Kawade Y, Kohase M, Klein JP. The neutralization of interferons by antibody. II. Neutralizing antibody unitage and its relationship to bioassay sensitivity: the tenfold reduction unit. J Interferon Cytokine Res 2001; 21:743-55. (Pubitemid 32955704)
10. Grossberg SE, Kawade Y, Kohase M, Yokoyama H, Finter N. The neutralization of interferons by antibody. I. Quantitative and theoretical analyses of the neutralization reaction in different bioassay systems. J Interferon Cytokine Res 2001; 21:729-42.
11. Blank VC, Sterin-Prync A, Retegui L, Vidal A, Criscuolo M, Roguin LP. Identification of a linear epitope of interferon-alpha2b recognized by neutralizing monoclonal antibodies. Eur J Biochem 1999; 265:11-9. (Pubitemid 29466007)
12. Redlich PN, Hoeprich PD, Colby CB, Grossberg SE. Antibodies that neutralize human beta interferon biologic activity recognize a linear epitope: analysis by synthetic peptide mapping. Proc Natl Acad Sci USA 1991; 88:4040-4. (Pubitemid 21916760)
13. Bellomi F, Muto A, Palmieri G, Focaccetti C, Dianzani C, Mattei M, Jaber A, Antonelli G. Immunogenicity comparison of interferon beta-1a preparations using the BALB/c mouse model: assessment of a new formulation for use in multiple sclerosis. New Microbiol 2007; 30:241-6. (Pubitemid 47264881)
14. Bertolotto A, Deisenhammer F, Gallo P, Solberg Sorensen P. Immunogenicity of interferon beta: differences among products. J Neurol 2004; 251:15-24.
15. Rossman HS. Neutralizing antibodies to multiple sclerosis treatments. J Manag Care Pharm 2004; 10: 12-9.